Observational Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Jan 21, 2017; 23(3): 533-539
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.533
Table 1 Clinical symptoms in the control and experimental groups before treatment n (%)
Indices (clinical symptoms)Control group (n = 30)Experimental group (n = 90)t/χ2P value
Stomach ache17 (56.67)50 (55.56)0.0250.874
Time to defecation (-x ± s)8.50 ± 1.318.71 ± 1.40-0.7230.471
Blood and pus10 (33.33)29 (32.22)0.0280.867
Tenesmus13 (43.33)38 (42.22)0.0250.874
Interleukin-8 (ng/L)25.83 ± 3.0124.97 ± 2.981.3660.175
Table 2 Clinical symptoms of patients in the two groups after treatment n (%)
GroupStomach acheTime to defecation (-x ± s )Blood and pusTenesmus
Control group
Before treatment17 (56.67)8.50 ± 1.3110 (33.33)13 (43.33)
After treatment13 (43.33)2.91 ± 0.975 (16.67)7 (23.33)
t/χ23.54818.7847.4019.000
P value0.0600.0000.0070.003
Experimental group
Before treatment50 (55.56)8.71 ± 1.4029 (32.22)38 (42.22)
After treatment8 (8.89)a1.12 ± 0.87a4 (4.44)a6 (6.67)a
t/χ249.86443.68425.77634.213
P value0.0000.0000.0000.000
Table 3 Comparison of interleukin-8 expression levels between the control and experimental groups
GroupDifferent time points
MeanFP value
Day 0Day 10Day 20Day 30
Control group25.83 ± 3.0125.23 ± 2.8724.68 ± 2.9924.34 ± 2.9825.02 ± 2.952.1910.060
Experimental group24.97 ± 2.9822.20 ± 2.9015.95 ± 2.628.81 ± 2.1317.98 ± 2.549.7150.000
Mean25.40 ± 2.9523.72 ± 2.8820.32 ± 2.7116.58 ± 2.3519.26 ± 2.526.1140.008
t1.3664.96915.24931.11712.617(F = 5.491, P = 0.032)1(F = 2.981, P = 0.139)2
P value0.1750.0000.0000.0000.000
Table 4 Adverse reactions in the control and experimental groups after treatment
GroupStomach discomfortLiver and kidney dysfunctionHeadacheRashesVomitingNeck painIncidence
Control group51322043.33%
Experimental group0000077.78%